What is Melanotan II?
Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), engineered at the University of Arizona in the early 1990s as part of a program to develop compounds that could tan skin without UV exposure. The underlying rationale was skin cancer prevention — if you could pre-tan skin before sun exposure, you might reduce UV-induced DNA damage. The compound works — Melanotan II produces rapid, significant skin darkening and has robust effects on sexual function via melanocortin receptor activation. It also has serious safety concerns that ended its pharmaceutical development.
The mechanism is non-selective melanocortin receptor agonism. MC1R activation drives melanin synthesis — producing the tanning effect. MC3R and MC4R activation drives the sexual function and appetite-reduction effects (the same receptors targeted more selectively by PT-141). The non-selectivity is both the compound's appeal and its primary risk: MC1R activation stimulates all melanocytes, including atypical or dysplastic ones. Rapid, uncontrolled melanocyte stimulation without dermatological monitoring creates real melanoma risk.
PT-141 (bremelanotide) was developed as a safer, more selective alternative — it targets MC3R and MC4R for sexual function without MC1R tanning activation, and received FDA approval for HSDD. For users interested in sexual function enhancement, PT-141 is the pharmacologically superior and legally approved option. Melanotan II's tanning effect is its unique application — but that benefit comes with melanoma risk that PT-141 doesn't carry.
How it works
MC1R Activation — Tanning
MC1R is expressed on melanocytes — the cells responsible for melanin production. Melanotan II's MC1R agonism produces melanin synthesis without UV, generating a deep tan from within. The tan is real melanin in the skin, not a surface coloring. The appeal for tanning without UV-triggered DNA damage is genuine — but the simultaneous stimulation of atypical melanocytes is the risk.
MC3R and MC4R Activation — Sexual Function and Appetite
MC4R activation in the hypothalamus and limbic system drives sexual desire and arousal via dopamine pathway engagement. MC3R modulation reduces appetite. These sexual function effects are robust and often described as more potent than PT-141 — reflecting Melanotan II's broader melanocortin receptor activation.
The Non-Selectivity Problem
Melanotan II activates all five melanocortin receptors (MC1R through MC5R) rather than selectively targeting specific receptors. Non-selective MC1R activation means all melanocytes are stimulated — including those with pre-existing mutations or atypical characteristics. This is the mechanistic basis for the melanoma risk.
What the research shows
Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study
Wessells H, Fuciarelli K, Hansen J et al.
Double-blind, placebo-controlled crossover study in 10 men with psychogenic erectile dysfunction (not healthy volunteers). A single 0.025 mg/kg subcutaneous dose of Melanotan II produced clinically apparent erections in 8 of 10 men, with mean tip rigidity above 80% lasting 38 minutes versus 3 minutes on placebo (p=0.0045). Nausea was more frequent than on placebo, along with stretching, yawning and decreased appetite — all transient, none requiring treatment. Tanning was not an endpoint in this trial.
View on PubMed →Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study
Dorr RT, Lines R, Levine N et al.
The original human Melanotan II study — the tanning trial the compound is known for. In 3 male volunteers, daily subcutaneous MT-II (escalated to ~0.025–0.03 mg/kg over two weeks) produced visible, measurable increases in skin pigmentation on the face, upper body and buttocks that persisted at least a week after dosing stopped. It also mapped MT-II's signature side-effect profile: mild nausea, a stretching-and-yawning complex, and spontaneous penile erections lasting 1–5 hours. Small and preliminary, but the foundational proof that MT-II tans human skin.
View on PubMed →DEVELOPMENT HALTED — REGULATORY POSITION
Melanotan II's pharmaceutical development was halted specifically because regulatory agencies found the safety signals unacceptable — primarily the unmonitored melanocyte stimulation risk. The MHRA (UK) has specifically stated it is illegal to sell Melanotan II for human use. Multiple case reports document melanoma developing in users following Melanotan II use. This is not a theoretical concern.
What the community reports
Common misconceptions
"The tan from Melanotan II is just cosmetic and safe."
The tan is real melanin produced by real melanocyte activation — including activation of atypical melanocytes. Regulatory agencies in multiple countries have issued specific warnings. Multiple case reports document melanoma in users. The cosmetic effect is real; so is the risk.
"Melanotan II is legal because it's sold as a research chemical."
'Research chemical' is a vendor framing, not a regulatory category. The MHRA has specifically stated it's illegal to sell Melanotan II for human use in the UK. In the US, it's not FDA-approved and sale for human use is technically illegal. Vendors operate in a gray zone.
"If my moles get bigger it just means it's working."
Mole darkening and size changes are the primary melanoma risk signal. Any changes to existing moles — darkening, size increase, border irregularity, color variation — require immediate dermatological evaluation. Not weeks later. Within days.
"PT-141 is basically the same thing."
PT-141 selectively targets MC3R and MC4R for sexual function without activating MC1R — no tanning, no melanoma risk, FDA-approved. For sexual function, PT-141 is the medically supervised option. Melanotan II's unique feature is UV-free tanning; that unique benefit comes with melanoma risk PT-141 does not carry.
FDA-APPROVED ALTERNATIVE FOR SEXUAL FUNCTION
PT-141 (Bremelanotide) selectively targets MC3R and MC4R for sexual function. FDA-approved for HSDD in women. No MC1R activation, no tanning, no melanoma risk. For sexual function applications, PT-141 is the pharmacologically superior and legally approved option.
Open PepperLedger to log your Melanotan II protocol →
Free to join. No credit card. Dermatological monitoring tracking built in.
Free to join · No credit card · 23-day Pro trial included
Registered trials and extra catalog links. These are not Study cards — a registry page is not proof of efficacy.
- ClinicalTrials.gov · recruiting · NCT07437560Melanotan II adjunct to NB-UVB for nonsegmental vitiligo